Published in the Daily Record, 9/14/20

GlycoT Therapeutics LLC, a UM Ventures startup company based on intellectual property developed at the University of Maryland, Baltimore and University of Maryland, College Park, executed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo Company, Limited, GlycoT officials said Monday.


The agreement grants Daiichi Sankyo worldwide and non-exclusive rights to IP that GlycoT currently licenses from UMB and UMCP, and includes an undisclosed upfront payment, annual fees, and adequate royalties of sales to GlycoT.

GlycoT’s enzymatic glycoengineering technology provides a platform to precisely change and modify the sugars on antibodies. Daiichi Sankyo plans to use this cutting-edge technology to prepare new drug candidates.

Lai-Xi Wang, Ph.D., founder and president of GlycoT Therapeutics and UMCP professor in the Department of Chemistry and Biochemistry, developed the technologies that are the basis for the GlycoT/Daiichi Sankyo license agreement in his lab, first at UMB and later at UMCP.